

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR 1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 20446-003US1	Application No. 10/584,020
	Applicant Simon Delagrave			
	Filing Date June 22, 2006		Group Art Unit	

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/00/	AA	US 3773919	11/20/73	Boswell et al.			
	AB	US 4485045	11/27/84	Regen			
	AC	US 4544545	10/01/85	Ryan et al.			
	AD	US 5914245	6/22/99	Bylina et al.			
	AE	US 20010044135	11/22/01	Stahi et al.			
	AF	US 20020037999	3/28/02	Mayer			
	AG	US 20020160424	10/31/02	Adler et al.			
	AH	US 20030059827	3/27/03	Gonzalez et al.			
	AI	US 20030119716	6/26/03	Ho et al.			
	AJ	US 6677438	1/13/04	Garnett et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/00/	AK	EP 36676 B2	9/30/81	Europe				
	AL	EP 52322 B2	5/26/82	Europe				
	AM	EP 88046 B1	9/07/83	Europe				
	AN	DE 3218121	11/17/83	Germany				
	AO	EP 102324 A2	3/07/84	Europe				
	AP	EP 133988 A2	3/13/85	Europe				
/00/	AQ	EP 142641 B1	5/29/85	Europe				
/00/	AR	EP 143949 B1	6/12/85	Europe				
/00/	AS	EP 58481 B1	10/01/86	Europe				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/00/	AT	A Practical Approach (M. J. MacPherson et al., eds. (1995)*)
/00/	AU	A Practical Approach (M. MacPherson et al. IRL Press at Oxford University Press (1991)*)
/00/	AV	Ames, et al., J Biol Chem 271,20231-20234 (1996)

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20446-003US1	Application No. 10/584,020
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Simon Delagrave	
		Filing Date June 22, 2006	Group Art Unit
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/00/	AW	Animal Cell Culture (R.I. Freshney ed. (1987)*
/00/	AX	Antibodies, A Laboratory Manual (Harlow and Lane eds. (1988)*
/00/	AY	Barbas et al., Proc. Natl. Acad.Sci. USA, 1992,9,10164
/00/	AZ	Chen et al., Biotechnology, 1991,9, 1073-1077
/00/	BA	Chen et al., Proc. Natl. Acad. Sci. USA, 1993,90, 5618-5622
/00/	BB	Chen et al., Biotechnology, 1991,9; 1073-1077
/00/	BC	Chen et al., Proc.Natl. Acad. Sci. USA, 1993,90, 5618-5622
/00/	BD	Cho et al., Neuron 9: 929-942,1992
/00/	BE	Cohen et al.,1998, J Cell Biol,142 : 129-38
/00/	BF	Current Protocols in Molecular Biology (F. M.Ausubel et al. eds. (1987)*
/00/	BG	Daniels et al.,1998, Nat Struct Biol, 5: 317- 25
/00/	BH	Delagrave et al., ProteinEng., 1993,6,327-331
/00/	BI	Doyle et al., Cell . 85 :1067-1076,1996
/00/	BJ	Epstein et al., Proc. Natl. Acad. Sci. U. S. A., 1985,82, 3688
/00/	BK	Fan et al., 2002,Neurosignals, 11 : 315-21
	BL	Ferre et al., 2002, Anal Biochem, 301 : 207-16
/00/	BM	Fitch, et al., Circulation 100,2499-2506(1999)
/00/	BN	Fuglsang, Protein Expr Purif. 2003,31 : 247-9
/00/	BO	Fuh et al., 2000, J. Biol. Chem. 275: 21486-91
/00/	BP	Gerard, et al. Complement in allergy and asthma. Curr Opin Immunol 14, 705-708 (2002)
/00/	BQ	Goldman and Youvan, Biotechnology (N Y), 1992, 10,1557-61
/00/	BR	Hamilton et al., 2003, Protein Sci, 12: 458-67
/00/	BS	Hanes & Pluckthun, Proc. Natl. Acad. Sci. USA, 1997, 94, 4937
/00/	BT	Harlow and Lane eds. and Sambrook et al. Molecular Cloning (1988)*
/00/	BU	Herlyn, et al., Science, 1986,232 : 100
/00/	BV	Horton et al., 1990, Biotechniques, 8,528
/00/	BW	Humbles, et al. Nature 406,998-1001 (2000)

Examiner Signature /Oluwatosin Ogunbiyi/	Date Considered 12/12/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20446-003US1	Application No. 10/584,020
	Applicant Simon Delagrave		
	Filing Date June 22, 2006	Group Art Unit	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/00/	BX	Hung et al., 2002, J Biol Chem, 277: 5699-702
	BY	Hwang et al., Proc. Natl. Acad. Sci. U. S. A., 1980, 77, 4030
	BZ	Im et al., 2003, J Biol Chem, 278: 8501-7
	CA	Inada et al., J. Bioactive Compat. Polymer 5, 343, 1990
	CB	Joo et al., Chem. Biol., 1999, 6, 699-706
	CC	Joo et al., Nature, 1999, 399, 670-673
	CD	Junqueira et al., 2003, Oncogene, 22: 2772-81
/00/	CE	Kawamoto, et al., J Clin Invest, 114, 399-407 (2004)
/00/	CF	Keefe et al., 2001, Nature, 410 : 715-8
/00/	CG	Kim et al., Nature 378: 85-88, 1995
/00/	CH	Kornau et al., Science 269: 1737-1740, 1995
/00/	CI	Langer et al., J Biomed. Mater. Res., 1981, 15, 167
/00/	CJ	Langer, Chem. Tech., 1982, 12, 98
/00/	CK	Leung et al., Technique, 1989, 1, 11-15
/00/	CL	Itoh et al., J. Cell. Biol. 121 : 491-502, 1993
/00/	CM	Marrs et al., Curr. Opin. Microbiol., 1999, 2, 241-245
/00/	CN	Miyazaki et al., J. Mol. Evol., 1999, 49, 716-720
/00/	CO	Morais Cabral et al., 1996, Nature, 382 : 649-52
/00/	CP	Nucci et al., Advan. Drug Del. Rev. 6, 133, 1991
/00/	CQ	Oi, et al., BioTechniques, 1986, 4 (3), 214
/00/	CR	Phage Displcly. A Laboratory Manual (C. F. Barbas III et al., (2001)*
/00/	CS	Ponting and Philips, Trends Biochem. Sci. 20:102-103, 1995
/00/	CT	Reina et al., 2002, Nat Struct Biol, 9: 621-7
/00/	CU	Ronnmark et al., 2002, Eur J Biochem, 269: 2647-55
/00/	CV	Sambrook, et al., Molecular Cloning. A Laboratory Manual, 2nd edition (1989)*
/00/	CW	Sato et al., 1995
/00/	CX	Schneider et al., 1999, Nature Biotechnology 17 : 170-175

Examiner Signature /Oluwatosin Ogunbiyi/	Date Considered 12/12/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 20446-003US1	Application No. 10/584,020
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Simon Delagrave	
		Filing Date June 22, 2006	Group Art Unit
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/OO/	CY	Sherman, et al., AnnThorac Snrg 77,942-949 (2004)
/OO/	CZ	Sidman et al., Biopolymers, 1983,22, 547
/OO/	DA	Singh, Nat. Struct.Biol., 2000,7 : 617-9
↓	DB	Skelton et al.(2003) , J.Biol. Chem. , 278: 7645-54
	DC	Smith, . Science, 1985, 228,1315
	DD	Spira, et al., J. Immunol. Methods, (1984) 74:307
	DE	Stemmer et al., Gene, 1993,123 :1-7
	DF	Steplewski, et al. Proc. Natl. Acad.Sci., 1985, 82, 8653
	DG	Stubbs, TrendsPharmacol Sci, 2002,23 : 539-41
	DH	Tatiana A. Tatusova and Thomas L. Madden(1999)*
/OO/	DI	Wadia and Dowdy, 2002, Curr Op Biotechnol, 13 : 52-6
↓	DJ	Woods and Bryant, Cell 66: 451-464,1991
	DK	Xu et al., Chem. Biol, 2002,9, 933
	DL	You et al., Protein Eng, 1996,9,77-83
/OO/	DM	Zeytun et al., 2003, Nat Biotechnol, 21 :1473-9

* Not enclosed, available upon request.

Examiner Signature /Oluwatosin Ogunbiyi/	Date Considered 12/12/2007
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	